PLRX stock forecast, quote, news & analysis
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies... Show more
Why Pliant Therapeutics (PLRX) Stock Is Down -19% in the Last 30 Days
Key Takeaways
- Pliant Therapeutics (PLRX) shares fell about 19% over the last 30 days, sliding from roughly $1.00 to near $0.81 as of early November 2026.
- The decline extends a longer slide: the stock is down approximately 22% over the trailing quarter and sits near the low end of its 12-month range.
- Sentiment remains weak as the company pivots away from discontinued lead candidate bexotegrast toward an earlier-stage oncology program and a preclinical delivery platform.
- Third-quarter 2026 results and recent ESMO and SITC conference presentations did not halt the selling pressure.
- The stock trades below its 50-day (about $1.05) and 200-day (about $1.17) moving averages, with a market capitalization near $55 million.
- Analysts hold a consensus Hold rating, with average price targets well above the current share price.
- For more detail on this ticker, review Pliant's Price Targets, Earnings, and Forecast.
- To see how algorithmic strategies are trading this name, explore Tickeron's Trending AI Robots.
Pliant Therapeutics (PLRX) Company Overview and Market Position
Pliant Therapeutics is a clinical-stage biopharmaceutical company based in South San Francisco that develops integrin-based therapeutics. Its lead program is PLN-101095, an oral, small-molecule, dual-selective inhibitor of the αvβ8 and αvβ1 integrins being evaluated for immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. PLN-101095 is currently in the FORTIFY Phase 1a/1b trial, studied in combination with pembrolizumab in patients with non-small cell lung cancer, tumors with high mutational burden, or clear cell renal cell carcinoma.
The company is also advancing preclinical research on an integrin-targeting platform designed to deliver drug payloads, including siRNAs, to specific tissues such as skeletal muscle. Investors follow PLRX for its oncology readouts, its cash position, and the optionality embedded in its platform technology, though the pipeline is earlier-stage following the discontinuation of its former lead candidate, bexotegrast.
Pliant Therapeutics (PLRX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, PLRX declined roughly 19%, from a closing price near $1.00 to about $0.81. The move was not a single-session shock but a steady grind lower punctuated by higher-volume down days in mid-October and around the early-November earnings report.
The last quarter tells a similar story on a longer timeframe. From a starting point near $1.05 in early August, the stock briefly rallied to a peak near $1.19 in late August before reversing lower and finishing near $0.81, a decline of roughly 22% over the period. The overall trend has been decisively downward, with the shares breaking below $1.00 and remaining below their 50-day and 200-day moving averages.
What Drove PLRX Stock Price in the Last 30 Days
Several factors contributed to the recent decline. Pliant reported third-quarter 2026 results in early November, and the shares moved lower into and through the report. The company remains in a post-reset phase after discontinuing bexotegrast, and its clinical catalysts are now tied to a Phase 1 oncology program and earlier-stage platform work, which carry longer timelines and greater uncertainty.
Conference presentations during the period—including the European Society for Medical Oncology (ESMO) Congress in late October and the Society for Immunotherapy of Cancer (SITC) Annual Meeting in early November—showcased PLN-101095 data but did not shift investor sentiment. The company also announced the appointment of a senior vice president for its siRNA research program, underscoring its focus on platform development. Throughout, the shares traded below $1.00, with the market capitalization hovering near $55 million even as the company retains a substantially larger cash balance.
What Drove PLRX Stock Performance Over the Last Quarter
The quarterly downtrend reflects a broader re-rating following the discontinuation of bexotegrast. With the IPF program removed from the pipeline, Pliant's most advanced asset is now an oncology candidate in Phase 1 testing, and the nearest meaningful catalysts are further out. A brief rally into the high-$1.10s in late August faded as investors reassessed the value of a smaller, earlier-stage pipeline against ongoing cash burn.
Macro conditions for small-cap, clinical-stage biotechs also remained challenging, with risk-off sentiment limiting support for pre-revenue names. The result has been a persistent downward bias, with PLRX grinding toward the low end of its 12-month range and trading below its long-term moving averages.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots drawn from the hundreds of bots available on the platform, which together trade thousands of tickers. Only the top-performing and most relevant bots appear in this section, each with its own strategy, timeframe, and performance metrics. Whether you are interested in short-term signals or longer-horizon approaches, this page offers a way to observe how algorithmic systems are positioned across the market. Explore the Trending AI Robots page to see which automated strategies are currently capturing attention.
PLRX Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors are likely to monitor several factors. Data updates and enrollment progress for the FORTIFY Phase 1b trial of PLN-101095 will be central, as will any disclosure around the company's siRNA delivery platform and its initial therapeutic indications. Quarterly earnings and updates on cash runway and operating expenses will also matter, given the company's cash position relative to its market capitalization.
Regulatory and listing considerations tied to trading below $1.00, analyst rating changes, and broader biotech sentiment could all influence the shares. As with any clinical-stage company, clinical, regulatory, and financing outcomes remain uncertain, and these factors—not short-term price moves—are likely to shape the stock's longer-term direction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for PLRX turns negative, indicating new downward trend
PLRX saw its Momentum Indicator move below the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned negative. In 81 of the 87 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for PLRX turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 43 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PLRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for PLRX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +4.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where PLRX advanced for three days, in 197 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
PLRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. PLRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.341) is normal, around the industry mean (3.498). P/E Ratio (-0.540) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. PLRX's P/S Ratio (3333.333) is slightly higher than the industry average of (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PLRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
Why Do You Want to Own the Shares of a Publicly Traded Corporation?
What are some strategies for diversifying a portfolio?
If I Want to Establish a Self-Employed 401(k), Do I Have to Establish One for All Owners of My Business?
Analyzing Bitcoin's Position: Insights from Top 5 Cryptocurrency Funds
What is a currency certificate?
General Information
a company which engages in the business of developing and commercializing novel therapies for fibrotic diseases
Industry Biotechnology